Nasdaq1mon
Cullinan Therapeutics Reports Phase 1 Study Updates and Financial Results for Q4 2024
Enrollment continues in the ongoing Phase 1 study of CLN-619 in patients with relapsed/refractory multiple myeloma. In January 2025, Cullinan announced that the pivotal Phase 2b portion of ...
WGN Radio1mon
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Enrollment continues in the ongoing Phase 1 study of CLN-619 in patients with relapsed/refractory multiple myeloma. Zipalertinib (EGFR ex20ins inhibitor), collaboration with Taiho Oncology: EGFR ...
WWLP-22News1mon
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Enrollment continues in the ongoing Phase 1 study of CLN-619 in patients with relapsed/refractory multiple myeloma. Zipalertinib (EGFR ex20ins inhibitor), collaboration with Taiho Oncology ...
Finanznachrichten3mon
Cullinan Therapeutics, Inc.: Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Enrollment continues in the ongoing Phase 1 study of CLN-619 in patients with relapsed/refractory multiple myeloma. Zipalertinib (EGFR ex20ins inhibitor), collaboration with Taiho Oncology ...